Other analysts have also issued research reports about the stock. HSBC restated a buy rating and set a GBX 1,970 ($24.40) target price on shares of GlaxoSmithKline plc in a research report on Monday, September 12th. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 27th. Berenberg Bank set a GBX 1,885 ($23.35) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Tuesday, August 9th. Sanford C. Bernstein set a GBX 1,834 ($22.72) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Wednesday, October 19th. Finally, S&P Global Inc. set a GBX 1,650 ($20.44) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline plc has a consensus rating of Hold and an average target price of GBX 1,723.54 ($21.35).
GlaxoSmithKline plc (LON:GSK) opened at 1573.50 on Monday. The firm’s market cap is GBX 76.57 billion. The firm has a 50 day moving average of GBX 1,642.88 and a 200 day moving average of GBX 1,582.95. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56.
The company also recently announced a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Thursday, November 3rd will be paid a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.17%. The ex-dividend date of this dividend is Thursday, November 3rd.
In related news, insider Manvinder Singh Banga purchased 1,750 shares of the company’s stock in a transaction on Wednesday, October 26th. The shares were bought at an average cost of GBX 1,643 ($20.35) per share, for a total transaction of £28,752.50 ($35,615.63). Also, insider Sir Andrew P. Witty sold 10,000 shares of the business’s stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($20.27), for a total transaction of £163,600 ($202,650.81).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.